Please upgrade your browser

We built this website using the latest browser technologies to deliver the very best experience.

This makes the site run faster and easier to use. Unfortunately, your browser is out of date and will not support some of these technologies.

We recommend that you use a modern browser such as Google Chrome or Microsoft Edge to view this website.

Download ChromeDownload Microsoft Edge
Back to team page

Dr. David Ruau

Chief Scientific Officer
David is a leader in the application of Big Data and AI to pharmaceutical research & development with deep expertise in the use of genomic and real-world patient data in pharmaceutical discovery and development.

Before joining Sensyne he served as Head of Global Data Assets and Decision Science at Bayer where he led teams working on the development and application of AI solutions in oncology, radiology and women’s health, including Sensyne’s collaboration with Bayer.

Prior to joining Bayer, David was Head of Scientific Computing Solutions at AstraZeneca working on data science solutions in the late-phase development pipeline to improve efficiency in designing and analysing clinical trials.  Before moving to the pharmaceutical industry, David had an academic career at RWTH Aachen, Stanford and Cambridge Universities. He has authored over 30 papers in publications such as Nature, Science and Cell, including well received research using real world data to study pain differences between genders and across diseases.